BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 25529339)

  • 1. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
    Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
    Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
    Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
    Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
    Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
    Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-Fio2 Strategy on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.
    Beitler JR; Sarge T; Banner-Goodspeed VM; Gong MN; Cook D; Novack V; Loring SH; Talmor D;
    JAMA; 2019 Mar; 321(9):846-857. PubMed ID: 30776290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
    Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
    Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
    Sadeghi B; Ringdén O; Gustafsson B; Castegren M
    Front Immunol; 2022; 13():963445. PubMed ID: 36426365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
    Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
    Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
    Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.
    Farge D; Loisel S; Resche-Rigon M; Lansiaux P; Colmegna I; Langlais D; Charles C; Pugnet G; Maria ATJ; Chatelus E; Martin T; Hachulla E; Kheav VD; Lambert NC; Wang H; Michonneau D; Martinaud C; Sensebé L; Cras A; Tarte K
    Lancet Rheumatol; 2022 Feb; 4(2):e91-e104. PubMed ID: 38288741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential application of mesenchymal stromal cells as a new therapeutic approach in acute respiratory distress syndrome and pulmonary fibrosis.
    Gazzaniga G; Voltini M; Carletti A; Lenta E; Meloni F; Briganti DF; Avanzini MA; Comoli P; Belliato M
    Respir Res; 2024 Apr; 25(1):170. PubMed ID: 38637860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
    Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
    Front Immunol; 2022; 13():932360. PubMed ID: 35860245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
    Dixon B; Smith RJ; Campbell DJ; Moran JL; Doig GS; Rechnitzer T; MacIsaac CM; Simpson N; van Haren FMP; Ghosh AN; Gupta S; Broadfield EJC; Crozier TME; French C; Santamaria JD;
    Lancet Respir Med; 2021 Apr; 9(4):360-372. PubMed ID: 33493448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Autologous Bone Marrow-derived Mesenchymal Stromal Cells Delay Acute Respiratory Distress Syndrome in Swine.
    Batchinsky AI; Roberts TR; Antebi B; Necsoiu C; Choi JH; Herzig M; Cap AP; McDaniel JS; Rathbone CR; Chung KK; Cancio LC
    Am J Respir Crit Care Med; 2023 Dec; 208(12):1283-1292. PubMed ID: 37797214
    [No Abstract]   [Full Text] [Related]  

  • 19. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
    Villar J; Ferrando C; Martínez D; Ambrós A; Muñoz T; Soler JA; Aguilar G; Alba F; González-Higueras E; Conesa LA; Martín-Rodríguez C; Díaz-Domínguez FJ; Serna-Grande P; Rivas R; Ferreres J; Belda J; Capilla L; Tallet A; Añón JM; Fernández RL; González-Martín JM;
    Lancet Respir Med; 2020 Mar; 8(3):267-276. PubMed ID: 32043986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; McAuley DF; O'Kane C
    Trials; 2022 May; 23(1):401. PubMed ID: 35562778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.